Facebook Linkedin Twitter
Inside Precision Medicine Lilly’s Phase III Combination Antibody Trial for COVID-19 Shows 87% Risk Reduction

Phase III clinical trials (Drug development)

Coronavirus, virus, flu, bacteria close-up. Abstract 3D rendered illustration
Coronavirus

Lilly’s Phase III Combination Antibody Trial for COVID-19 Shows 87% Risk Reduction

0
Antibodies responding to COVID-19 coronavirus, illustration
Coronavirus

International Phase III Trial of Long-Acting Antibodies for COVID-19 Launched

0
corona virus 1
Coronavirus

Novavax and Janssen Report Positive Phase III Results for COVID-19 Vaccine Candidates

0
Gloved hand holding COVID-19 vaccine such as the mRNA vaccine developed by Arcturus Therapeutics in syringe on a background of SARS-CoV-2 particles
Coronavirus

What Can We Expect From The Second Wave of Coronavirus Vaccines?

Helen Albert
0
brain tumor
News & Features

Biomarker-Guided Therapy for Newly Diagnosed Glioblastoma Kicks off Phase III Trial

0
Coronavirus Covid-19 Vaccine
Coronavirus

Novavax’s COVID-19 Vaccine Candidate Moves into Phase III Trial

0
Antibodies responding to covid-19 coronavirus, illustration
Coronavirus

Pfizer, BioNTech Final Phase III Data Show COVID-19 Vaccine 95% Effective

0
Pfizer and BioNTech’s SARS-CoV-2 Vaccine More Than 90% Effective at Initial Phase III Readout
Coronavirus

Pfizer and BioNTech’s SARS-CoV-2 Vaccine More Than 90% Effective at Initial Phase III Readout

0
NIH Launches COVID-19 Clinical Trial of Immune Modulators
Coronavirus

NIH Launches COVID-19 Clinical Trial of Immune Modulators

0
Latest COVID-19 Phase III Trial Pause: Eli Lilly’s Antibody Therapy Candidate
News & Features

Latest COVID-19 Phase III Trial Pause: Eli Lilly’s Antibody Therapy Candidate

0
1...5678Page 6 of 8

Related Content

Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.
Inside Precision Medicine